Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world comparison of paricalcitol, calcitriol, and cinacalcet in hemodialysis patients with CKD-MBD and secondary hyperparathyroidism
ChiCTR1900026679Phase 4Not yet recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paricalcitol, calcitriol and cinacalcet in secondary hyperparathyroidism (SHPT) and chronic kidney disease-mineral and bone disorder (CKD-MBD) (3 arms), sponsored by Changzhou Second People's Hospital. Primary endpoint: Percentage of iPTH decline. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
paricalcitolcalcitriolcinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease-mineral and bone disorder (CKD-MBD)
Beyond the preview
Go deeper on ChiCTR1900026679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026679.